{"raw_mentions": "FIG. 5 shows the IC50 values for bendamustine, the compound of formula I and vorinostat against five different Hodgkin lymphoma cell lines;\nFIG. 6B shows the IC50 values for bendamustine, the compound of formula I and vorinostat against three different Hodgkin lymphoma cell lines;"}
{"final_json": [{"molecule_name": "bendamustine", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "IC50", "value": null, "unit": null}, {"molecule_name": "the compound of formula I", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "IC50", "value": null, "unit": null}, {"molecule_name": "vorinostat", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "IC50", "value": null, "unit": null}, {"molecule_name": "bendamustine", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "IC50", "value": null, "unit": null}, {"molecule_name": "the compound of formula I", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "IC50", "value": null, "unit": null}, {"molecule_name": "vorinostat", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "IC50", "value": null, "unit": null}]}
{"raw_mentions": "Here are the extracted sentences:\n\n1.56 \u03bcM of EDO-S101 was administered to two Hodgkin lymphoma cell lines, the bendamustine na\u00efve cell line L1236 and the bendamustine resistant cell line R100.\nBrentuximab Vedotin was administered at a concentration of 3.12 \u03bcg/ml to the L1236 cell line and at a concentration of 0.39 \u03bcg/ml to the R100 cell line.\nMost importantly, it was found that EDO-S101 at sub-IC50 levels is synergistic with Brentuximab Vedotin in inducing cell death of L1236 cells and furthermore that at sub-IC concentrations EDO-S101 allows low doses of Brentuximab Vedotin (typically 10-fold lower than IC50) to exert a considerable cyctotoxic effect on bendamustine resistant R100 cells."}
{"final_json": [{"molecule_name": "EDO-S101", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "1.56", "unit": "\u03bcM"}, {"molecule_name": "Brentuximab Vedotin", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "3.12", "unit": "\u03bcg/ml"}, {"molecule_name": "Brentuximab Vedotin", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "0.39", "unit": "\u03bcg/ml"}, {"molecule_name": "EDO-S101", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "IC50", "value": "sub-IC50", "unit": null}, {"molecule_name": "EDO-S101", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "IC", "value": "sub-IC", "unit": null}, {"molecule_name": "Brentuximab Vedotin", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "IC50", "value": "10-fold lower than IC50", "unit": null}]}
